[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Cooperative Study
July 1973

Psoriasis-Liver-Methotrexate Interactions

Author Affiliations

University of Miami School of Medicine, Miami, Fla; Cleveland Clinic, Cleveland; University of California, San Francisco; University of Miami School of Medicine, Miami, Fla; London Hospital, London; New York University, New York; Cleveland Clinic, Cleveland; Clyde Computing Service, Miami, Fla; the Royal Victoria Infirmary, Newcastle-upon-Tyne, England; University of Miami School of Medicine, Miami, Fla; Duke University, Durham, NC; University of California, San Francisco; University of Lund, Lund, Sweden; Mount Sinai School of Medicine, New York; Royal Free Hospital, London; Marselisborg Hospital, Copenhagen

Arch Dermatol. 1973;108(1):36-42. doi:10.1001/archderm.1973.01620220008002
Abstract

An international cooperative study was organized to evaluate whether the treatment of severe psoriasis with methotrexate significantly affects the liver of these patients. From a study population of 550 patients, 742 liver biopsy specimens together with pertinent clinical and laboratory data were evaluated as a function of methotrexate usage.

Factors found to be significantly associated with histologic liver damage include: increased alcohol intake, the daily orally administered methotrexate dosage schedule, obesity, and diabetes. The evidence implicating increasing cumulative methotrexate dosage as a cause of hepatic fibrosis is not clear. Of 247 patients with biopsyproven fibrosis or cirrhosis, 88 patients had no recorded abnormalities in history, physical examination, or laboratory test results which casts serious doubt on the reliability of detecting fibrosis or cirrhosis without a liver biopsy.

×